T cell receptor profiling in Psoriatic Arthritis.
- Conditions
- arthritis psoriaticapsoriatic arthropathy10014982
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 60
Psoriatic Arthritis group;
1.Age; 18-75 years
2.Joint inflammation of one or both knees due psoriatic artritis.
3.Patients require systemic treatment.
4.have failed to respond to, or have a contraindication for cyclosporine and other DMARDS exept MTX.;Psoriasis group;
1.Age; 18-75 years
2.Patients have psoriasis and a severity index (PASI) of 10 or more then 10 and/or Body Surface Area (BSA) of 10 or more then 10 and/or PASI of 8 or less then 8 together with skindex of 35 or more then 35.
3. Patients have psoriasis in their history for at least 10 years.
4. Patients have no signs of joint inflammation, nor in their history.
5.Patients require systemic treatment.
6.Patients have failed to respond to, or have a contraindication for cyclosporine and other DMARDS exept MTX.
Pregnancy and lactation- active (or chronic) infections including Hepatitis B and C viral infections, HIV and tuberculosis- Malignancy in last 10 years, exept BCC and cervical insitu cancer- treatment with a biological stopped because of inefficacy, contraindication or serious adverse events, after biological therapy for minimal 12 weeks-demyelinating disease-congestive heart failure-allergies and hypersensitivities to potential anti-rheumatic drugs or their ingredients-any live virus or bacterial vaccination within 3 months- severe liver function disorders > 2 timesand/or kidney function disorders > 1,5 times upper limits of the reference values.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Typing of pathogenic T cell population in skin an joints;<br /><br>1.T-cell receptor (TCR-G) profile.<br /><br>2.Gene expression profile.</p><br>
- Secondary Outcome Measures
Name Time Method <p>1.Effects of anti-arthritic therapy on pathogenic T cells.</p><br>